IMN || Conferences

Advanced age no barrier to continuous myeloma regimen

VIENNA – Elderly patients over age 75 with newly diagnosed multiple myeloma derive the same survival benefits from continuous lenalidomide and low-dose dexamethasone as those under 75, according to a...

Field of Interest: Oncology
Type: News Item

Pages

Subscribe to RSS - IMN || Conferences